A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-05-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: womenstudy requirementsdysfunctiondecreasedtreatment for
  Phrases that lowered it: healthyevaluate thedisorderand safetyto evaluate
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 2.2% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: not given (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder NCT02338960 · started 2015 · scored riskier than 8% of active trials completed
• 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder NCT02333071 · started 2014 · scored riskier than 8% of active trials completed
• BP101 for Adults With Female Sexual Dysfunction NCT03463707 · started 2018 · scored riskier than 9% of active trials completed
• Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire NCT03080298 · started 2016 · scored riskier than 14% of active trials completed
• Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women NCT00996372 · started 2009 · scored riskier than 78% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.